Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Schering's Proventil

Executive Summary

Switchovers to Repetabs formula of beta-agonist bronchodilator accounted for one-third of all Proventil tablet sales in 1988, not one-third of the asthma drug's total volume, as reported in the March 20 issue of "The Pink Sheet" (T&G-6). Repetabs sales represent about 6% of total $ 100 mil. Proventil sales. The product is a b.i.d. formulation. Proventil inhaler volume is roughly $ 59 mil., followed in order by $ 19 mil. for solution form, $ 13 mil. for tablets and roughly $ 3 mil. for Proventil syrup.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS015321

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel